POLICY WIRE FACT CHECK: Pentagon’s $41M Investment in Singaporean Ketamine Wafers
The Claim In early October, a viral narrative spread across social media platforms alleging that the U.S. Department of Defense (DOD) had awarded a high-value contract to a foreign pharmaceutical...
The Claim
In early October, a viral narrative spread across social media platforms alleging that the U.S. Department of Defense (DOD) had awarded a high-value contract to a foreign pharmaceutical company to produce ‘ketamine wafers.’ The claim specifically identified the developer of the product as a Singapore-based entity known as iX Biopharma. The product, dubbed ‘Wafermine,’ was described as a small wafer designed to dissolve under the tongue, delivering ketamine through the mucous membrane to bypass the need for injections.
The viral post gained significant traction, with users questioning the safety and ethics of providing a controlled substance to military personnel via a non-invasive method. The claim suggested a massive financial commitment, totaling approximately $41 million, leading to public concern regarding military procurement and the use of potent drugs in the field.
The Details & Investigation
An investigation into official corporate filings and government statements reveals that the core of the viral claim is accurate. On February 12, 2024, iX Biopharma issued a formal announcement stating that the U.S. government would provide $40,954,914 in funding to support the development of Wafermine. The company described the product as the world’s first patented sublingual racemic ketamine wafer specifically developed for acute moderate to severe pain. Unlike many viral rumors that involve fabricated or secret deals, this transaction was a documented funding agreement aimed at researching and developing a pre-hospital analgesic solution.
The Defense Health Agency (DHA), a combat support agency within the DOD, confirmed that the development of pain management solutions for warfighters is a strategic priority. According to a DHA official, they discovered iX Biopharma and Wafermine through standard market research on analgesic ketamine products. The agency noted that the solution has a 10-year track record of pre-hospital use in Australia, making it a viable candidate for military requirements. The DHA emphasized that the process is subject to standard regulatory oversight, with a preference for domestic manufacturing to strengthen the military supply chain.
In evaluating the nature of this claim, it does not fall under the category of deliberate disinformation. While the social media discussion may have lacked context regarding the regulatory hurdles and the specific nature of the development phase, the facts regarding the amount, the entity, and the product type are all verified by iX Biopharma’s annual reports and official DHA statements. The investment is described in the company’s own annual report as the ‘defining event of the year,’ highlighting its significance as a legitimate research and development contract rather than a secret purchase of an already-market drug.
The Verdict
The claim that the U.S. Department of Defense is investing approximately $41 million in the development of ketamine wafers from iX Biopharma is TRUE. This is supported by iX Biopharma’s own news releases and official statements from the Defense Health Agency. The funding is designated for the research and development of a sublingual delivery system intended to provide pain management for warfighters in pre-hospital settings without requiring injections.
Counter-misinformation & disinformation investigation conducted by PolicyWire Editorial Desk (PW).
